Susquehanna International Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.45M | Buy |
33,800
+6,900
| +26% | +$916K | ﹤0.01% | 4446 |
|
|
2025
Q4 | $3.82M | Sell |
26,900
-118,200
| -81% | -$17.1M | ﹤0.01% | 4482 |
|
|
2025
Q3 | $20.4M | Buy |
145,100
+29,800
| +26% | +$4.04M | ﹤0.01% | 2189 |
|
|
2025
Q2 | $14.5M | Buy |
115,300
+10,800
| +10% | +$1.24M | ﹤0.01% | 2381 |
|
|
2025
Q1 | $11.6M | Buy |
104,500
+13,200
| +14% | +$1.67M | ﹤0.01% | 2338 |
|
|
2024
Q4 | $12.5M | Sell |
91,300
-51,000
| -36% | -$6.31M | ﹤0.01% | 2386 |
|
|
2024
Q3 | $16.4M | Sell |
142,300
-22,400
| -14% | -$3.07M | ﹤0.01% | 2032 |
|
|
2024
Q2 | $22.7M | Sell |
164,700
-15,200
| -8% | -$2.08M | ﹤0.01% | 1600 |
|
|
2024
Q1 | $24.8M | Buy |
179,900
+15,200
| +9% | +$2.08M | ﹤0.01% | 1569 |
|
|
2023
Q4 | $21.7M | Sell |
164,700
-21,100
| -11% | -$2.43M | ﹤0.01% | 1727 |
|
|
2023
Q3 | $20.9M | Buy |
185,800
+42,000
| +29% | +$4.42M | ﹤0.01% | 1696 |
|
|
2023
Q2 | $13.6M | Buy |
143,800
+95,300
| +196% | +$9.31M | ﹤0.01% | 2133 |
|
|
2023
Q1 | $4.91M | Buy |
48,500
+12,900
| +36% | +$1.34M | ﹤0.01% | 3503 |
|
|
2022
Q4 | $4.25M | Sell |
35,600
-28,200
| -44% | -$3.3M | ﹤0.01% | 3484 |
|
|
2022
Q3 | $6.78M | Buy |
63,800
+26,000
| +69% | +$2.64M | ﹤0.01% | 2704 |
|
|
2022
Q2 | $3.69M | Sell |
37,800
-4,800
| -11% | -$443K | ﹤0.01% | 3717 |
|
|
2022
Q1 | $3.99M | Sell |
42,600
-27,900
| -40% | -$2.36M | ﹤0.01% | 4066 |
|
|
2021
Q4 | $6M | Buy |
70,500
+6,000
| +9% | +$552K | ﹤0.01% | 3445 |
|
|
2021
Q3 | $6.19M | Sell |
64,500
-18,400
| -22% | -$1.74M | ﹤0.01% | 3592 |
|
|
2021
Q2 | $8.07M | Sell |
82,900
-63,000
| -43% | -$6.04M | ﹤0.01% | 3226 |
|
|
2021
Q1 | $14.2M | Buy |
145,900
+47,300
| +48% | +$4.96M | ﹤0.01% | 2301 |
|
|
2020
Q4 | $9.45M | Sell |
98,600
-7,400
| -7% | -$715K | ﹤0.01% | 2571 |
|
|
2020
Q3 | $10.2M | Sell |
106,000
-40,400
| -28% | -$4.67M | ﹤0.01% | 2145 |
|
|
2020
Q2 | $17.9M | Buy |
146,400
+56,200
| +62% | +$6.21M | ﹤0.01% | 1526 |
|
|
2020
Q1 | $7.81M | Sell |
90,200
-100,800
| -53% | -$9.86M | ﹤0.01% | 2041 |
|
|
2019
Q4 | $20.5M | Buy |
191,000
+73,800
| +63% | +$7.73M | 0.01% | 1394 |
|
|
2019
Q3 | $10.6M | Buy |
117,200
+12,800
| +12% | +$1.2M | ﹤0.01% | 1921 |
|
|
2019
Q2 | $8.81M | Sell |
104,400
-7,600
| -7% | -$624K | ﹤0.01% | 2013 |
|
|
2019
Q1 | $9.87M | Sell |
112,000
-265,100
| -70% | -$22.2M | ﹤0.01% | 1760 |
|
|
2018
Q4 | $26.9M | Buy |
377,100
+283,100
| +301% | +$27.1M | 0.01% | 903 |
|
|
2018
Q3 | $11.6M | Sell |
94,000
-41,800
| -31% | -$4.74M | ﹤0.01% | 1785 |
|
|
2018
Q2 | $13.3M | Sell |
135,800
-134,700
| -50% | -$12.1M | ﹤0.01% | 1657 |
|
|
2018
Q1 | $22.4M | Buy |
270,500
+113,800
| +73% | +$9.61M | 0.01% | 1135 |
|
|
2017
Q4 | $12.2M | Buy |
156,700
+92,700
| +145% | +$6.32M | ﹤0.01% | 1667 |
|
|
2017
Q3 | $3.92M | Sell |
64,000
-39,700
| -38% | -$2.09M | ﹤0.01% | 2835 |
|
|
2017
Q2 | $4.77M | Sell |
103,700
-88,800
| -46% | -$4.31M | ﹤0.01% | 2473 |
|
|
2017
Q1 | $8.34M | Buy |
192,500
+145,500
| +310% | +$6.23M | ﹤0.01% | 1797 |
|
|
2016
Q4 | $1.82M | Sell |
47,000
-172,500
| -79% | -$7.81M | ﹤0.01% | 4258 |
|
|
2016
Q3 | $11.1M | Sell |
219,500
-202,800
| -48% | -$10.1M | 0.01% | 1444 |
|
|
2016
Q2 | $19.2M | Buy |
422,300
+225,500
| +115% | +$10.4M | 0.01% | 1005 |
|
|
2016
Q1 | $7.78M | Sell |
196,800
-4,500
| -2% | -$179K | ﹤0.01% | 1794 |
|
|
2015
Q4 | $11.4M | Sell |
201,300
-27,800
| -12% | -$1.41M | 0.01% | 1640 |
|
|
2015
Q3 | $9.12M | Sell |
229,100
-114,300
| -33% | -$5.52M | ﹤0.01% | 1932 |
|
|
2015
Q2 | $16.4M | Buy |
343,400
+172,300
| +101% | +$7.31M | 0.01% | 1501 |
|
|
2015
Q1 | $6.79M | Sell |
171,100
-107,200
| -39% | -$3.83M | ﹤0.01% | 2314 |
|
|
2014
Q4 | $6.22M | Buy |
278,300
+71,200
| +34% | +$1.35M | ﹤0.01% | 2580 |
|
|
2014
Q3 | $3.25M | Sell |
207,100
-13,100
| -6% | -$196K | ﹤0.01% | 3758 |
|
|
2014
Q2 | $3.27M | Sell |
220,200
-22,100
| -9% | -$312K | ﹤0.01% | 3775 |
|
|
2014
Q1 | $3.9M | Buy |
242,300
+8,800
| +4% | +$151K | ﹤0.01% | 3245 |
|
|
2013
Q4 | $2.18M | Sell |
233,500
-212,700
| -48% | -$2.08M | ﹤0.01% | 4125 |
|
|
2013
Q3 | $5.05M | Buy |
446,200
+275,300
| +161% | +$3.78M | ﹤0.01% | 2722 |
|
|
2013
Q2 | $2.29M | Buy |
+170,900
| New | +$2.1M | ﹤0.01% | 3699 |
|
Other funds holding NBIX
VPM
VCM
Susquehanna International Group's NBIX Position: Q1 2026 in Review
Susquehanna International Group reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q1 2026, selling an estimated $1.32M and leaving 87,727 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2898.
Susquehanna International Group first reported a position in NBIX in Q2 2013 and has held it in 45 quarters since. The position peaked at $20.7M in Q3 2020. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Susquehanna International Group held 87,727 shares of Neurocrine Biosciences worth $11.6M as of Q1 2026.
- Susquehanna International Group sold 9,986 Neurocrine Biosciences shares in Q1 2026, an estimated $1.32M.
- Neurocrine Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2898 holding.
- Susquehanna International Group first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 45 quarters since.
- Susquehanna International Group's Neurocrine Biosciences position peaked at $20.7M in Q3 2020.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.